Comparison Chart Protagonist Therapeutics, Inc.

Stocks

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
134.44 ^USD	+4.42%		-7.21%	+53.93%

10-12	UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target	MT
09-11	Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	PROTAGONIST THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+4.42%	-7.21%	+53.93%	+73.47%	+352.81%	8.7B